2 active not recruiting, 2 completed, 1 recruiting. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 2, Completed 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow OSE Immunotherapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg - Solid Advanced Tumor, Lymphoma | Phase 1 / Phase 2 | Recruiting | OSE Immunotherapeutics | 41 | 2022-12-20 | 2026-06-04 |
| OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC OSE2101, Pembrolizumab 25 MG/ML [Keytruda] - Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Active not recruiting | ARCAGY/ GINECO GROUP | 185 | 2021-08-05 | 2026-11-02 |
| Phase I/II Study of FR104 First Administration In Patient With Renal Transplantation: FIRsT Study FR104 - Kidney Transplantation | Phase 1 / Phase 2 | Completed | Nantes University Hospital | 10 | 2021-06-28 | 2026-01-15 |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC FOLFIRI, OSE2101 - Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer | Phase 2 | Active not recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 106 | 2021-04-10 | 2025-07-25 |
| Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis OSE-127, Placebo - Ulcerative Colitis | Phase 2 | Completed | OSE Immunotherapeutics | 136 | 2020-10-02 | 2026-06-23 |
Carcinoma, Non-Small-Cell Lung (1) · Colitis, Ulcerative (1) · Inflammatory Bowel Diseases (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Recurrence (1)
Fluorouracil (1) · IFL protocol (1) · Irinotecan (1) · Leucovorin (1) · pembrolizumab (1)
France (4) · Belgium (3) · Belarus (1) · Bulgaria (1) · Croatia (1) · Georgia (1) · Germany (1) · Hungary (1) · Latvia (1) · Poland (1) · Russia (1) · South Africa (1) · Spain (1) · Ukraine (1)
Silvia Comis, MD (1)